dehydroepiandrosterone has been researched along with Prostatic Neoplasms, Castration-Resistant in 12 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Conclusion Low-dose AA (with low-fat breakfast) is noninferior to standard dosing with respect to PSA metrics." | 2.87 | Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ( Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP, 2018) |
| "Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen deprivation therapy (ADT) by various genetic actions." | 2.52 | Reconsideration of progression to CRPC during androgen deprivation therapy. ( Mizokami, A; Namiki, M, 2015) |
| "In castration-resistant prostate cancer patients, levels of androstenedione were significantly associated with testosterone level, while testosterone was the only steroid associated with dihydrotestosterone levels." | 1.72 | Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level. ( Caron, P; Guillemette, C; Lacombe, L; Lévesque, É; Morin, F; Neveu, B; Pouliot, F; Rouleau, M; Toren, P; Turcotte, V, 2022) |
| "Most patients with prostate cancer receiving enzalutamide or abiraterone develop resistance." | 1.56 | Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. ( Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Li, PK; Liu, C; Liu, L; Lombard, AP; Lou, W; Ning, S; Yang, JC; Zhao, J; Zhao, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y | 1 |
| Wu, S | 1 |
| Chong, Y | 1 |
| Guan, B | 1 |
| Li, L | 1 |
| He, D | 1 |
| Wang, X | 1 |
| Wang, B | 1 |
| Wu, K | 1 |
| Rouleau, M | 1 |
| Neveu, B | 1 |
| Caron, P | 1 |
| Morin, F | 1 |
| Toren, P | 1 |
| Lacombe, L | 1 |
| Turcotte, V | 1 |
| Lévesque, É | 1 |
| Guillemette, C | 1 |
| Pouliot, F | 1 |
| Armstrong, CM | 1 |
| Liu, C | 1 |
| Liu, L | 1 |
| Yang, JC | 1 |
| Lou, W | 1 |
| Zhao, R | 1 |
| Ning, S | 1 |
| Lombard, AP | 1 |
| Zhao, J | 1 |
| D'Abronzo, LS | 1 |
| Evans, CP | 1 |
| Li, PK | 1 |
| Gao, AC | 1 |
| Qin, S | 1 |
| Liu, D | 1 |
| Kohli, M | 1 |
| Wang, L | 2 |
| Vedell, PT | 1 |
| Hillman, DW | 1 |
| Niu, N | 1 |
| Yu, J | 1 |
| Weinshilboum, RM | 1 |
| Szmulewitz, RZ | 1 |
| Peer, CJ | 1 |
| Ibraheem, A | 1 |
| Martinez, E | 1 |
| Kozloff, MF | 1 |
| Carthon, B | 1 |
| Harvey, RD | 1 |
| Fishkin, P | 1 |
| Yong, WP | 1 |
| Chiong, E | 1 |
| Nabhan, C | 1 |
| Karrison, T | 1 |
| Figg, WD | 1 |
| Stadler, WM | 1 |
| Ratain, MJ | 1 |
| Hettel, D | 1 |
| Zhang, A | 1 |
| Alyamani, M | 1 |
| Berk, M | 1 |
| Sharifi, N | 2 |
| Hamid, ARAH | 1 |
| Tendi, W | 1 |
| Sesari, SS | 1 |
| Mochtar, CA | 1 |
| Umbas, R | 1 |
| Verhaegh, G | 1 |
| Schalken, JA | 1 |
| Sabharwal, N | 1 |
| Doherty, D | 1 |
| Dvorkin, SA | 1 |
| Rodriguez, EP | 1 |
| Thompson, PD | 1 |
| Mizokami, A | 1 |
| Namiki, M | 1 |
| Labrie, F | 1 |
| Maity, SN | 1 |
| Titus, MA | 1 |
| Gyftaki, R | 1 |
| Wu, G | 1 |
| Lu, JF | 1 |
| Ramachandran, S | 1 |
| Li-Ning-Tapia, EM | 1 |
| Logothetis, CJ | 1 |
| Araujo, JC | 1 |
| Efstathiou, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)[NCT01953640] | 92 participants (Actual) | Observational | 2013-05-28 | Active, not recruiting | |||
| A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer[NCT01543776] | Phase 2 | 72 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA[NCT05623059] | Phase 1/Phase 2 | 9 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Extragonadal serum adrogen (NCT01543776)
Timeframe: Cycle 4 (4 months)
| Intervention | microgram per deciliter (Mean) |
|---|---|
| Arm I (Fasting) | 13.30 |
| Arm II (Fed) | 10.22 |
Data were analyzed on a log scale: log(week 12) - log(baseline) = log ratio. Smaller (more negative) values indicate a better outcome. (NCT01543776)
Timeframe: From baseline to 12 weeks
| Intervention | log ratio (Mean) |
|---|---|
| Arm I (Fasting) | -1.19 |
| Arm II (Fed) | -1.59 |
Patients with grade 3 or higher AE (CTCAE Version 4.03) (NCT01543776)
Timeframe: Assessed up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Fasting) | 6 |
| Arm II (Fed) | 11 |
Analyzed on a log scale due to skewness of distribution (NCT01543776)
Timeframe: Up to 4 months
| Intervention | log(ng/mL) (Mean) |
|---|---|
| Arm I (Fasting) | 5.39 |
| Arm II (Fed) | 4.65 |
Time to PSA progression (25% increase from baseline), radiographic progression, or death. (NCT01543776)
Timeframe: Assessed up to 3 years
| Intervention | Months (Median) |
|---|---|
| Arm I (Fasting) | 8.6 |
| Arm II (Fed) | 8.6 |
4 reviews available for dehydroepiandrosterone and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
The importance of targeting intracrinology in prostate cancer management.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Agents; Benzamides; Dehydroepia | 2019 |
HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
Topics: Adrenal Glands; Androgens; Dehydroepiandrosterone; Dietary Supplements; Genotype; Humans; Male; Mult | 2019 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Mal | 2015 |
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamid | 2015 |
1 trial available for dehydroepiandrosterone and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Dehydroepiandrosterone; Dose-Response Relat | 2018 |
7 other studies available for dehydroepiandrosterone and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling.
Topics: Aldo-Keto Reductase Family 1 Member C3; Androgens; Animals; Cell Line, Tumor; Dehydroepiandrosterone | 2022 |
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Topics: Androgen Antagonists; Androgens; Androstenedione; Androsterone; Dehydroepiandrosterone; Dihydrotesto | 2022 |
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Pro | 2020 |
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Cell Cycle Proteins; Cell Proliferation; Cytochrome P-450 CYP3A; Cytochrome P-4 | 2018 |
AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Topics: Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; | 2018 |
Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Topics: Androgens; Calcitriol; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP3A; Cytochrome P-45 | 2014 |
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androgens; Animals; Biopsy; Cell Line, Tumor; Dehydroepiandrosterone; Humans; H | 2016 |